DarioHealth Corp.
NASDAQ:DRIOMedical - Diagnostics & Research
-$0.12 today
- Market cap
- $50.27M
- Beta
- 1.08
- P/E (TTM)
- 5.5
- EPS (TTM)
- $1.26
Volume 0.01M
Average 0.01M
DRIO Cost of Revenue
Direct costs of producing the goods and services sold, such as materials, manufacturing, and service delivery.
DarioHealth Corp.NASDAQ: DRIO
Cost of Revenue · Q1 FY2026 · quarter ended Mar 2026
Cost of revenue declines year over year
Q1 FY2026 cost of revenue of $2.38M fell 16.9% year over year, behind the -2.6% change in trailing-twelve-month cost of revenue. Sequentially, it fell 16.6% from the prior quarter. Over 3 fiscal years it compounded at -18.6% a year.
Context
- Cost of revenue amounted to 43.4% of revenue in FY2025, down 7.6 pp from a year earlier.
- Cost of revenue increased in 0 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth recovers from -16.9% toward the trailing-twelve-month pace of -2.6%.
Sources:Income StatementText generated from reported figures; not investment advice.
Cost of Revenue history
USD · from the income statement
- Latest · FY2025
- 9.69M USD
- Year-over-year change
- -29.6%
- 4-year CAGR
- -6.1%
| Period | Period end | Cost of Revenue | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 9.69M | -29.6% |
| FY2024 | 2024-12-31 | 13.77M | -4.1% |
| FY2023 | 2023-12-31 | 14.37M | -20.2% |
| FY2022 | 2022-12-31 | 18M | +44.7% |
| FY2021 | 2021-12-31 | 12.44M | — |
Cost of Revenue vs competitors
How DRIO compares with its peers on the latest reported figures
- DRIO's LTM Mar 2026 cost of revenue of $9.21M is the 9th highest of the 11 companies compared; the peer median is $148.51M.
- Its year-over-year change of -2.6% is the 6th highest of 10, against a peer median of -0.1%.
- Cost of revenue amounts to 43.5% of revenue for DRIO, versus a peer median of 56.4%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $749.65M | +9.8% | -21.8% | 79.3% | |
| LTM Mar 2026 | $368.3M | +18.2% | +6.7% | 51.4% | |
| LTM Mar 2026 | $255.74M | -3.2% | +29.9% | 31.0% | |
| LTM Mar 2026 | $249M | -0.1% | +7.1% | 30.0% | |
| LTM Mar 2026 | $196.33M | +9.7% | -8.7% | 61.3% | |
| LTM Mar 2026 | $100.69M | -21.2% | +11.3% | 62.9% | |
| LTM Mar 2026 | $87.94M | +139.2% | -28.1% | 100.1% | |
| LTM Mar 2026 | $26.01M | -49.9% | -41.6% | 1416.9% | |
| LTM Mar 2026 | $9.21M | -2.6% | -18.6% | 43.5% | |
| LTM Mar 2026 | $8.06M | — | — | 16.3% | |
NNNNAnbio Biotechnology Class A Ordinary Shares | FY2025 | $1.25M | -45.8% | -51.6% | 12.8% |
| Peer median (excluding DRIO) | $148.51M | -0.1% | -8.7% | 56.4% | |
Competitors are the stored peer set for DRIO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 20.51M | 27.66M | 20.35M | 27.04M | 22.36M |
| Cost of Revenue | 12.44M | 18M | 14.37M | 13.77M | 9.69M |
| Gross Profit | 8.07M | 9.66M | 5.98M | 13.27M | 12.67M |
| Gross Margin | 39.3% | 34.9% | 29.4% | 49.1% | 56.6% |
| Research & Development | 17.22M | 19.65M | 20.25M | 24.18M | 13.79M |
| Selling, General & Admin | 62.36M | 46.82M | 41.8M | 46.83M | 35.53M |
| Operating Expenses | 84.56M | 66.47M | 62.17M | 71.01M | 49.32M |
| Depreciation & Amortization | 4.46M | 4.72M | 4.99M | 7.43M | 3.56M |
| EBITDA | (70.02M) | (55.6M) | (54.38M) | (37.08M) | (34.69M) |
| EBITDA Margin | -341.3% | -201.0% | -267.2% | -137.1% | -155.2% |
| Operating Income | (76.49M) | (56.81M) | (56.19M) | (57.74M) | (36.66M) |
| Operating Margin | -372.9% | -205.4% | -276.1% | -213.6% | -163.9% |
| Interest Income | 44K | 506K | 1.87M | 1.12M | 943K |
| Interest Expense | 84K | 2.68M | 645K | 96K | 3.36M |
| Other Income / Expenses | (235K) | (5.38M) | (3.17M) | 13.15M | (4.95M) |
| Income Before Tax | (76.73M) | (62.19M) | (59.36M) | (44.6M) | (41.61M) |
| Pre-Tax Margin | -374.1% | -224.9% | -291.7% | -164.9% | -186.1% |
| Income Tax Expense | 32K | 4K | 64K | (1.85M) | 105K |
| Net Income | (76.76M) | (62.19M) | (59.43M) | (42.75M) | (41.71M) |
| Net Margin | -374.2% | -224.9% | -292.0% | -158.1% | -186.6% |
| EPS (Basic) | (4.63) | (2.63) | (1.93) | (0.74) | 1.24 |
| EPS (Diluted) | (4.63) | (2.63) | (1.93) | (0.74) | 1.24 |
| Weighted Avg Shares | 16.59M | 23.64M | 28.37M | 40.42M | 49.63M |
| Weighted Avg Shares (Diluted) | 16.59M | 23.64M | 28.37M | 40.42M | 49.63M |
DarioHealth Corp.
NASDAQ:DRIO
Intrinsic Alpha fair value
Locked
Current Price
$5.13
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.